Professor of Experimental Therapeutics Kapil Mehta earned one of four pilot grants awarded this year by the Pancreatic Cancer Action Network (PANCAN) and the American Association for Cancer Research.
The $195,870 two-year grant supports Mehta's ongoing inquiry into how overexpression of tissue transglutaminase (TG2) promotes pancreatic cancer drug resistance and metastasis.
He and other awardees were honored Tuesday night at the AACR Research Grants Dinner at its annual meeting in Denver.
Mehta has connected overexpression of the gene to treatment resistance and metastasis in pancreatic and breast cancer and melanoma. Mehta and colleagues have shown that expression of TG2 can be shut down with a targeted small-interfering RNA (siRNA).